Publications by authors named "D De Angeli"

Background: Tumor heterogeneity is a hurdle to effective therapy, as illustrated by the 'mixed responses' frequently seen in immunotherapy-treated patients. Previously, AXL+ tumor cells were identified to be highly resistant to targeted therapy, whereas more differentiated MITF+ tumor cells do respond to RAF and MEK inhibitors.

Patients And Methods: In this study, we analyzed tumor heterogeneity and explored the presence of the previously described AXL+ or MITF+ melanoma subpopulations in metastatic tissues by NanoString gene expression analysis, single-cell RNA sequencing and multiplex immunofluorescence.

View Article and Find Full Text PDF

Background: Adjuvant trastuzumab is the standard of care for HER2+ breast cancer (BC) patients. However, >50% of patients become resistant. This study aimed at the identification of the molecular factors associated with disease relapse and their further investigation as therapeutically exploitable targets.

View Article and Find Full Text PDF

: Patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (mBC) generally receive hormonal therapy (HT) combined with CDK4/6 inhibitors (CDK4/6i). Despite this treatment, resistance mechanisms to CDK4/6i emerge and the majority of these patients experience disease progression (PD). This highlight the necessity to uncover the resistance mechanism to CDK4/6i through the identification of specific biomarkers.

View Article and Find Full Text PDF
Article Synopsis
  • Hearing impairment can be masked by neurological disorders like Temporal Lobe Epilepsy (TLE), affecting communication and mental health.
  • A systematic review evaluated tools for assessing auditory processing deficits in TLE patients, revealing significant differences from normal controls in both behavioral and electrophysiological tests.
  • The findings highlight the necessity of assessing hearing efficiency first, as incomplete peripheral hearing evaluations can lead to misinterpretation of auditory processing capabilities.
View Article and Find Full Text PDF
Article Synopsis
  • * It involved surgical samples from EGC patients with a 10-year follow-up, using specialized genomic panels to examine molecular characteristics and pathway instability scores.
  • * Key findings indicated that the aggressive Pen A subtype has more ARID1A mutations and greater genetic instability, while LRP1B alterations were linked to a higher risk of relapse or death, suggesting potential markers for prognosis in EGC patients.
View Article and Find Full Text PDF